Hite Biopharma (300683.SZ): Epranamine for Injection Receives Drug Clinical Trial Approval

Zhitong Finance APP News, Hite Biopharma (300683.SZ) announced that the company recently received the "Drug Clinical Trial Approval Notice" (Notice No.: 2026LP02967) approved and issued by the National Medical Products Administration (hereinafter referred to as the "NMPA"). The clinical trial application for the company's declared Epranermin for Injection (trade name: Saite) has been approved by the NMPA, agreeing to conduct clinical trials of this product for chondrosarcoma.